Method
Level · gp.fundamentals.debt_to_revenue
Raw value 46.90% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTKura Oncology, Inc.'s latest supported as-filed period reports revenue of $20.9M, 36.5% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 46.90% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 3.14% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -299.65% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 36.54% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 11.90% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 98.84% · CORE
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents decreased 14.3%; Operating cash flow decreased 117.4%.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 36.5%; Operating margin moved 12555 bp higher; Operating income decreased 0.5%.
3 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 36.5%; Operating margin moved 12555 bp higher; Operating income decreased 0.5%.
3 evidence-backed componentsFree-cash-flow proxy changed -109.0% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
KURA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-387934SEC ↗8-KSep 9, 2026Period Sep 9, 20260001193125-26-385881SEC ↗8-KSep 8, 2026Period Sep 8, 20260001193125-26-384363SEC ↗4Aug 24, 2026Period Aug 24, 20260001193125-26-363812SEC ↗4Aug 24, 2026Period Aug 21, 20260001193125-26-363810SEC ↗4Aug 21, 2026Period Aug 19, 20260001193125-26-361184SEC ↗4Aug 17, 2026Period Aug 17, 20260001193125-26-354201SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Level · gp.fundamentals.operating_margin
Raw value -349.77% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 296.50% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 39.33% · OPTIONAL
Operating cash flow changed -117.4% from the comparable as-filed period.
Operating margin changed +12555 basis points from the comparable as-filed period.
Revenue changed +36.5% from the comparable as-filed period.
Working capital / assets changed -595 basis points from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Capex / revenue changed -639 basis points from the comparable as-filed period.
Trade receivables changed +106.5% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-346884